Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Filippo Bagnoli, Jacopo Calabrese De Feo, Francesca Livia Letizia Ricci, Jacopo Mariotti, Barbara Sarina, Monica Balzarotti, Daniela Taurino, Daniele Mannina, Chiara De Philippis, Daoud Rahal, Arturo Bonometti, Massimo Magagnoli, Rita Mazza, Marcello Rodari, Laura Giordano, Stefania Bramanti, Carmelo Carlo-Stella, Armando Santoro

Blood (2024) 144 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2024-203287

Published: 2024

Journal Articles

Clinical relevance of clonal hematopoiesis in persons aged ≥80 years

Marianna Rossi, Manja Meggendorfer, Matteo Zampini, Mauro Tettamanti, Emma Riva, Erica Travaglino, Matteo Bersanelli, Sara Mandelli, Alessia Antonella Galbussera, Ettore Mosca, Elena Saba, Chiara Chiereghin, Nicla Manes, Chiara Milanesi, Marta Ubezio, Lucio Morabito, Clelia Peano, Giulia Soldà, Rosanna Asselta, Stefano Duga, Carlo Selmi, Maria De Santis, Karolina Malik, Giulia Maggioni, Marilena Bicchieri, Alessia Campagna, Cristina A. Tentori, Antonio Russo, Efrem Civilini, Paola Allavena, Rocco Piazza, Giovanni Corrao, Claudia Sala, Alberto Termanini, Laura Giordano, Paolo Detoma, Aurelio Malabaila, Luca Sala, Stefano Rosso, Roberto Zanetti, Claudia Saitta, Elena Riva, Gianluigi Condorelli, Francesco Passamonti, Armando Santoro, Francesc Sole, Uwe Platzbecker, Pierre Fenaux, Niccolò Bolli, Gastone Castellani, Wolfgang Kern, George S. Vassiliou, Torsten Haferlach, Ugo Lucca, Matteo G. Della Porta

Blood (2021) 138 (21): 2093–2105.

https://doi.org/10.1182/blood.2021011320

Published: 2021

Includes: Supplemental data

Journal Articles

A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-138775

Published: 2020

Journal Articles

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Reid W Merryman, MD, Luca Castagna, MD, Paolo Corradini, MD, Vincent T. Ho, MD, David A. Bond, MD, Samantha Jaglowski, MDMPH, Michael A Spinner, Sally Arai, MD, Robert Lowsky, MD, Alex F. Herrera, MD, Anna Guidetti, MD, Geoffrey Shouse, DO, PhD, Didier Blaise, MD PhD, Jean Marc Schiano De Colella, MD, Talha Badar, MD, Mehdi Hamadani, MD, Stephen M Ansell, MD PhD, Yago Nieto, MD PhD, Chloe Spilleboudt, MD, Tatyana A. Feldman, MD, Lori Dahncke, BSN, Anurag K. Singh, MD, Joseph P. McGuirk, DO, Mohamad Mohty, MD PhD, Remy Dulery, MD, Aspasia Stamatoulas Bastard, Roch Houot, MD PhD, Guillaume Manson, MD, Marie-Pierre Moles, MD, Corentin Orvain, MD, Kamal Bouabdallah, MD, Matthew J. Frigault, MD, Yi-Bin Chen, Ryan C. Lynch, MD, Stephen D. Smith, MD, Uttam Rao, MD, Michael T Byrne, DO, Jason Romancik, MD, Jonathon B. Cohen, MDMS, Robin M. Joyce, MD, Maryam Rahimian, MD, Asad Bashey, MD PhD, Hatcher J. Ballard, BS, Jakub Svoboda, MD, Laura Giordano, Valter Torri, Beatrice Casadei, MD, Martina Sollini, MD, Chiara De Philippis, MD, Massimo Magagnoli, MD, Armando Santoro, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD PhD, Carmelo Carlo-Stella, MD

Blood (2019) 134 (Supplement_1): 775.

https://doi.org/10.1182/blood-2019-125039

Published: 2019

Journal Articles

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, MD, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, Flavia Salvi, Antonella Anastasia, MD, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, MD, Anna Marina Liberati, MD, Nicola Di Renzo, MD, Luca Castagna, MD, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2018-99-118931

Published: 2018

Journal Articles

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Armando Santoro, MD, Luca Castagna, MD, Massimo Magagnoli, MD, Stefania Bramanti, MD, Jacopo Mariotti, MD, Rita Mazza, MD, Lucia Morello, MD, Francesca Ricci, MD, Barbara Sarina, MD, Chiara De Philippis, MD, Simona Sica, MD, Marcello Rodari, MD, Martina Sollini, MD, Margarita Kirienko, MD, Laura Giordano, Arturo Chiti, MD, Paolo Corradini, MD, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2018-99-118127

Published: 2018

Journal Articles

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Blood (2018) 132 (Supplement 1): 1655.

https://doi.org/10.1182/blood-2018-99-115313

Published: 2018

Journal Articles

Reduced Relapse and Improved Survival in Chemosensitive Hodgkin Lymphoma Patients Undergoing Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation

Blood (2017) 130 (Supplement 1): 3309.

https://doi.org/10.1182/blood.V130.Suppl_1.3309.3309

Published: 2017

Journal Articles

Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network

Blood (2017) 130 (Supplement 1): 2959.

https://doi.org/10.1182/blood.V130.Suppl_1.2959.2959

Published: 2017

Journal Articles

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, MD, Flavia Salvi, MD, Antonella Anastasia, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, Anna Marina Liberati, MD, Nicola Di Renzo, Luca Castagna, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2015) 126 (23): 581.

https://doi.org/10.1182/blood.V126.23.581.581

Published: 2015

Journal Articles

Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma

Roberto Crocchiolo, MD PhD, Luca Castagna, MD, Sabine Fuerst, MD, Jean El Cheikh, MD, Barbara Sarina, MD, Stefania Bramanti, Angela Granata, MD, Lucio Morabito, MD, Laura Giordano, MD, Sylvain Garciaz, MD, Diane Coso, MD, Reda Bouabdallah, MD, Monica Balzarotti, Christian Chabannon, MD PhD, Carmelo Carlo-Stella, MD, Armando Santoro, MD, Didier Blaise, MD PhD

Blood (2014) 124 (21): 3863.

https://doi.org/10.1182/blood.V124.21.3863.3863

Published: 2014

Journal Articles

Tacrolimus (FK) Compared to Cyclosporine a (CyA) after Haploidentical T Cell Replete Stem Cell Transplantation (Haplo-SCT) with Post-Infusion Cyclophosphamide: A Retrospective Analysis

Luca Castagna, Stefania Bramanti, MD, Sabine Furst, Barbara Sarina, MD, Roberto Crocchiolo, MD PhD, Laura Giordano, MD, Jean El Cheikh, MD, Angela Granata, MD, Lucio Morabito, MD, Elisa Mauro, MD, Catherine Faucher, Bilal Mothy, Samia Harbi, MD, Christian Chabannon, MD PhD, Carmelo Carlo-Stella, MD, Armando Santoro, MD, Didier Blaise, MD

Blood (2014) 124 (21): 3902.

https://doi.org/10.1182/blood.V124.21.3902.3902

Published: 2014

Journal Articles

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Anna Guidetti, MD, Simonetta Viviani, MD, Alfonso Marchianò, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Silvia L Locatelli, PhD, Domenico Russo, Pietro Bulian, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Laura Giordano, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2012) 120 (21): 3679.

https://doi.org/10.1182/blood.V120.21.3679.3679

Published: 2012

Journal Articles

Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL)

Antonella Anastasia, MD, Carmelo Carlo-Stella, MD, Paolo Corradini, MD, Flavia Salvi, Chiara Rusconi, Alessandro Pulsoni, Stefan Hohaus, MD, Patrizia Pregno, Simonetta Viviani, MD, Ercole Brusamolino, MD, Stefano Luminari, Laura Giordano, MD, Armando Santoro, MD

Blood (2012) 120 (21): 3652.

https://doi.org/10.1182/blood.V120.21.3652.3652

Published: 2012

Journal Articles

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Massimo Magagnoli, Katia Marzo, MD, Monica Balzarotti, Marcello Rodari, Rita Mazza, Laura Giordano, MD, Sara Gandolfi, MD, Stefania Bramanti, Antonella Anastasia, MD, Fabio Romano Lutman, MD, Arturo Chiti, MD, Armando Santoro

Blood (2011) 118 (21): 93.

https://doi.org/10.1182/blood.V118.21.93.93

Published: 2011

Journal Articles

Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution

Massimo Magagnoli, Rita Mazza, Sara Gandolfi, Marcello Rodari, Laura Giordano, MD, Antonella Anastasia, MD, Egesta Lopci, Arturo Chiti, Armando Santoro, Monica Balzarotti

Blood (2011) 118 (21): 2674.

https://doi.org/10.1182/blood.V118.21.2674.2674

Published: 2011

Journal Articles

Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL)

Massimo Magagnoli, Monica Balzarotti, Antonella Anastasia, Rita Mazza, Laura Giordano, MD, Luca Castagna, Michele Spina, MD, Alessandra Romano, Stefania Bramanti, Armando Santoro

Blood (2010) 116 (21): 1761.

https://doi.org/10.1182/blood.V116.21.1761.1761

Published: 2010

Journal Articles

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Blood (2010) 115 (18): 3671–3677.

https://doi.org/10.1182/blood-2009-12-253856

Published: 2010

Journal Articles

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Antonella Anastasia, MD, Monica Balzarotti, Massimo Magagnoli, MD, Michele Spina, MD, Rita Mazza, MD, L. Castagna, Andrea Nozza, Stefania Bramanti, md, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro

Blood (2009) 114 (22): 1213.

https://doi.org/10.1182/blood.V114.22.1213.1213

Published: 2009

Journal Articles

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Rita Mazza, MD, Stefano Luminari, Massimo Magagnoli, MD, Michele Spina, MD, Teodoro Chisesi, MD, Antonio Pinto, MD, Massimo Federico, MD, Antonella Anastasia, MD, Arturo Chiti, MD, Mariagrazia Michieli, MD, Francesco Angrilli, MD, Luca Castagna, Giampaolo Marcacci, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro, Monica Balzarotti

Blood (2009) 114 (22): 3707.

https://doi.org/10.1182/blood.V114.22.3707.3707

Published: 2009

NARROW

Bendamustine in Combination with Gemcitabine and Vinorelbine As Salvage Regimen for Relapsed or Refractory Peripheral T-Cell Lymphomas: A Retrospective Single Center Experience

Clinical relevance of clonal hematopoiesis in persons aged ≥80 years

A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate

Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study

Reduced Relapse and Improved Survival in Chemosensitive Hodgkin Lymphoma Patients Undergoing Haploidentical Related Donor Compared to HLA-Identical Donor Transplantation

Clinical Implications of TP53 Mutations and p53 Dysfunction in Patients with Myelodysplastic Syndrome (MDS). a Study from the Italian MDS Clinical Network

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma

Tacrolimus (FK) Compared to Cyclosporine a (CyA) after Haploidentical T Cell Replete Stem Cell Transplantation (Haplo-SCT) with Post-Infusion Cyclophosphamide: A Retrospective Analysis

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Bendamustine for Relapsed/Refractory Classical Hodgkin Lymphoma After High Dose Chemotherapy and or Allogeneic Transplant: A Study of Fondazione Italiana Linfomi (FIL)

Dimension of Residual CT Scan Mass in Hodgkin's Lymphoma (HL) Is a Negative Prognostic Factor in Patients with PET Negative After Chemo+/− Radiotherapy

Result of FDG PET Imaging After Chemotherapy +/− Immunotherapy Is a Significant and Independent Prognostic Indicator of Outcome for Patients with Follicular Lymphoma: Survey From a Single Institution

Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL)

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Better Outcome with Tandem High DOSE CHEMOTHERAPY and AUTOLOGOUS STEM CELLS TRANSPLANT IN Relapsed/Refractory HODGKIN LYMPHOMA PATIENTS Which Reached COMPLETE REMISSION AFTER Ifosfamide- Gemcitabine-Vinorelbine Scheme (IGEV).

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only